Kamada KMDA 深 沪
等待开盘 07-17 09:30:00 美东时间
7.56
0.000
0.00%
华盛通- 最 高7.61
- 今 开7.59
- 成交量 4.41万股
- 最 低 7.50
- 昨 收 7.56
- 总市值 4.35亿
- 52周最高 8.955
- 市盈率 静 30.23
- 换手率 0.08%
- 52周最低 4.88
- 委 比 -91.46%
- 总股本 5750.50万
- 历史最高 17.75
- 量 比 0.70
- 振 幅 1.46%
- 历史最低 2.82
- 每 手 1
- 风险率 0.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多日本执政党或失去参议院多数！最新民调揭露巨大政治风险
①日本参议院选举在即，但据民调显示，执政联盟自民党和公明党可能失去多数席位，引发政治风险； ②选民对通货膨胀和自民党丑闻不满，而若执政联盟失势，可能引发首相石破茂辞职呼声； ③专家指出，执政党在众议院和参议院都只占少数是日本自二战以来从未经历过的局面，日本政坛前景不明。
07-16 15:23
CORRECTION: Kamada Reported Business Operations on June 17, 2025.
CORRECTION: Kamada Reported Business Operations on June 17, 2025.
06-25 03:34
Kamada Assures Uninterrupted Drug Supply as Israeli Operations Continue Despite Middle East Tensions
Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today
06-17 19:04
Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East
Kamada Ltd., a global biopharmaceutical company specializing in rare and serious conditions, announced that despite evolving circumstances in the Middle East, its Israeli facility continues operations and manufacturing as planned, ensuring business continuity and no expected disruption in global product availability. CEO Amir London stated that while shipments from Israel may be temporarily affected by airspace closures, sufficient product levels...
06-17 11:00
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
Benchmark Reiterates Buy on Kamada, Maintains $15 Price Target
Benchmark analyst Robert Wasserman reiterates Kamada (NASDAQ:KMDA) with a Buy and maintains $15 price target.
05-15 22:39
Earnings Scheduled For May 14, 2025
Companies Reporting Before The Bell • Cellebrite DI (NASDAQ:CLBT) is expected t...
05-14 16:32
Earnings Preview For Kamada
Kamada (NASDAQ:KMDA) is set to give its latest quarterly earnings report on Wed...
05-14 03:01
Kamada Announces Tax Ruling on Special Cash Dividend
Kamada ( ($IL:KMDA) ) just unveiled an announcement. On March 24, 2025, Kamada ...
03-24 19:27
美股大行评级 | 高盛：上调Adaptive Biotechnologies评级至"买入"，目标价从8美元升至9美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1110125309827231744.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Oppenheimer：维持Amprius Technologies(AMPX)"跑赢大市"评级，目标价从14美元升至15美元</p> <p>• 韦德布什：维持Monte Rosa Therapeutics(GLUE)"跑
03-24 07:31
